{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:15:12Z","timestamp":1785179712823,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Brandenburg CAMPUS GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The treatment of choice for substance use disorder (SUD) caused by sedatives, hypnotics, and anxiolytics (SHA) is to slowly taper the dose of the implicated substance to the point of abstinence, thereby minimizing withdrawal symptoms. Concomitant pharmacotherapy may be indicated to manage excessive withdrawal or rebound symptoms. This study investigated the use of psychotropic drugs for the treatment of SHA-dependent SUD patients in Germany.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data were obtained from the German <jats:italic>Drug Safety Program in Psychiatry<\/jats:italic> (\u201cArzneimittelsicherheit in der Psychiatrie\u201d; AMSP) from 2000 to 2017. SHA SUD was classified using the 10th Edition of the International Classification of Disease (ICD-10).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The present study included 1,015 patients with a primary diagnosis of mental and behavioral disorders due to use of sedatives or hypnotics (F13.1-F13.9). The most common comorbid psychiatric diagnoses were additional SUDs (F1, <jats:italic>n<\/jats:italic>\u2009=\u2009279), especially alcohol use disorder (F10; <jats:italic>n<\/jats:italic>\u2009=\u2009124), and mood disorders (F3; <jats:italic>n<\/jats:italic>\u2009=\u2009201). A total of 95.6% of patients received one or more psychotropic drugs, most commonly antidepressant drugs (63.1% of patients), tranquillizing drugs (55.5%), and antipsychotic drugs (46.7%). The most common combination was an antidepressant drug and a tranquillizing drug (33.0%). Overall, psychotropic drugs with sedating properties (e.g., mirtazapine, quetiapine, doxepin, and trimipramine) were preferred. An increase in use over the 17-year observation period was observed for tranquillizing drugs and, most pronounced, for antipsychotic drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We found high rates of non-SHA drugs among patients treated for SHA-SUD. The prevalent use of psychotropic drugs with strong sedating properties indicates a symptom-oriented treatment approach, which is often \u201coff-label\u201d but may be clinically necessary. Main limitation is the cross-sectional design of the AMSP databank. Therefore, we cannot provide any follow up data on the patient collective especially regarding outcome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13722-025-00579-6","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T01:32:53Z","timestamp":1750383173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacotherapy of psychiatric inpatients with mental and behavioral disorders caused by sedatives or hypnotics (F13): Results from an observational pharmacovigilance program between 2000 and 2017"],"prefix":"10.1186","volume":"20","author":[{"given":"Philipp","family":"Pauwels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Haack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phileas Johannes","family":"Proskynitopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"579_CR1","doi-asserted-by":"crossref","unstructured":"Shukla L, Bokka S, Shukla T, Kandasamy A, Chand P, Benegal V et al. Benzodiazepine and Z-Drug dependence: data from a tertiary care center. Prim Care Companion CNS Disord. 2017;19(1).","DOI":"10.4088\/PCC.16br02025"},{"issue":"12","key":"579_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147\u201357.","journal-title":"N Engl J Med"},{"issue":"11","key":"579_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1360-0443.2010.02933.x","volume":"105","author":"M Liebrenz","year":"2010","unstructured":"Liebrenz M, Boesch L, Stohler R, Caflisch C. Agonist substitution\u2013a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction. 2010;105(11):1870\u20134.","journal-title":"Addiction"},{"issue":"6","key":"579_CR4","first-page":"292","volume":"25","author":"J Fritze","year":"2018","unstructured":"Fritze J, Riedel C, Escherich A, Beinlich P, Broich K, Sudhop T. Anxiolytika und hypnotika: spektrum der verordnung und morbidit\u00e4t. Psychopharmakotherapie. 2018;25(6):292\u2013303.","journal-title":"Psychopharmakotherapie"},{"key":"579_CR5","first-page":"w13745","volume":"143","author":"F Hoffmann","year":"2013","unstructured":"Hoffmann F. Perceptions of German gps on benefits and risks of benzodiazepines and Z-drugs. Swiss Med Wkly. 2013;143:w13745.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"579_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jsmc.2017.09.002","volume":"13","author":"GS Brewster","year":"2018","unstructured":"Brewster GS, Riegel B, Gehrman PR. Insomnia in the older adult. Sleep Med Clin. 2018;13(1):13\u20139.","journal-title":"Sleep Med Clin"},{"issue":"7","key":"579_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamapsychiatry.2017.1273","volume":"74","author":"GA Bushnell","year":"2017","unstructured":"Bushnell GA, Sturmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent Long-term benzodiazepine use in adults with depression, united states, 2001\u20132014. JAMA Psychiatry. 2017;74(7):747\u201355.","journal-title":"JAMA Psychiatry"},{"key":"579_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.genhosppsych.2019.11.008","volume":"62","author":"M Enomoto","year":"2020","unstructured":"Enomoto M, Kitamura S, Tachimori H, Takeshima M, Mishima K. Long-term use of hypnotics: analysis of trends and risk factors. Gen Hosp Psychiatry. 2020;62:49\u201355.","journal-title":"Gen Hosp Psychiatry"},{"issue":"9","key":"579_CR9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/ijnp\/pyz037","volume":"22","author":"S Toto","year":"2019","unstructured":"Toto S, Grohmann R, Bleich S, Frieling H, Maier HB, Greil W, et al. Psychopharmacological treatment of schizophrenia over time in 30 908 inpatients: data from the AMSP study. Int J Neuropsychopharmacol. 2019;22(9):560\u201373.","journal-title":"Int J Neuropsychopharmacol"},{"key":"579_CR10","first-page":"CD001026","volume":"6","author":"Y Ogawa","year":"2019","unstructured":"Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev. 2019;6:CD001026.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"579_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1176\/ps.62.8.pss6208_0908","volume":"62","author":"CS Wu","year":"2011","unstructured":"Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in taiwan: a nationwide population-based survey. Psychiatr Serv. 2011;62(8):908\u201314.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"579_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/alcalc\/agg123","volume":"38","author":"BA Johansson","year":"2003","unstructured":"Johansson BA, Berglund M, Hanson M, Pohlen C, Persson I. Dependence on legal psychotropic drugs among alcoholics. Alcohol Alcohol. 2003;38(6):613\u20138.","journal-title":"Alcohol Alcohol"},{"issue":"6","key":"579_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1024\/0939-5911.a000275","volume":"59","author":"A Pabst","year":"2013","unstructured":"Pabst A, Kraus L, Matos EGd, Piontek D. Substanzkonsum und substanzbezogene st\u00f6rungen in Deutschland Im Jahr 2012. Sucht. 2013;59(6):321\u201331.","journal-title":"Sucht"},{"issue":"1","key":"579_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/dar.12304","volume":"35","author":"G Gmel","year":"2016","unstructured":"Gmel G, Holmes J, Studer J. Are alcohol outlet densities strongly associated with alcohol-related outcomes? A critical review of recent evidence. Drug Alcohol Rev. 2016;35(1):40\u201354.","journal-title":"Drug Alcohol Rev"},{"key":"579_CR15","unstructured":"Deutsche. Gesellschaft f\u00fcr psychiatrie und psychotherapie, psychosomatik und Nervenheilkunde e.v. (DGPPN), Deutsche gesellschaft f\u00fcr Suchtforschung und suchttherapie (DG-Sucht). S3-Leitlinie medikamentenbezogene St\u00f6rungen- 1. Auflage. Version 01. 2020. 2020;AWMF-Register-Nr.: 038\u2013\u2009025."},{"issue":"2","key":"579_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","volume":"70","author":"DT Maust","year":"2019","unstructured":"Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the united States. Psychiatr Serv. 2019;70(2):97\u2013106.","journal-title":"Psychiatr Serv"},{"key":"579_CR17","first-page":"260","volume-title":"Suchtmedizin","author":"M Vogel","year":"2019","unstructured":"Vogel M, Caflisch C. Sedativa und hypnotika. In: Soyka M, Batra A, Heinz A, Moggi F, Walter M, editors. Suchtmedizin. M\u00fcnchen: Elsevier; 2019. pp. 260\u201376."},{"issue":"6\u20137","key":"579_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/2045125317696454","volume":"7","author":"L Jacob","year":"2017","unstructured":"Jacob L, Rapp MA, Kostev K. Long-term use of benzodiazepines in older patients in germany: a retrospective analysis. Ther Adv Psychopharmacol. 2017;7(6\u20137):191\u2013200.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"10","key":"579_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","volume":"18","author":"G Airagnes","year":"2016","unstructured":"Airagnes G, Pelissolo A, Lavall\u00e9e M, Flament M, Limosin F. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep. 2016;18(10):89.","journal-title":"Curr Psychiatry Rep"},{"issue":"12","key":"579_CR20","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","volume":"106","author":"M Lader","year":"2011","unstructured":"Lader M. Benzodiazepines revisited\u2013will we ever learn? Addiction. 2011;106(12):2086\u2013109.","journal-title":"Addiction"},{"issue":"1","key":"579_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1600-0447.1987.tb02863.x","volume":"76","author":"G Laux","year":"1987","unstructured":"Laux G, Konig W. Long-term use of benzodiazepines in psychiatric inpatients. Acta Psychiatr Scand. 1987;76(1):64\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"579_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0447.1998.tb05973.x","volume":"393","author":"E Schweizer","year":"1998","unstructured":"Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl. 1998;393:95\u2013101.","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"2","key":"579_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1192\/bjp.bp.113.126003","volume":"204","author":"RL Gould","year":"2014","unstructured":"Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98\u2013107.","journal-title":"Br J Psychiatry"},{"key":"579_CR24","first-page":"CD011481","volume":"3","author":"L Baandrup","year":"2018","unstructured":"Baandrup L, Ebdrup BH, Rasmussen JO, Lindschou J, Gluud C, Glenthoj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018;3:CD011481.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"579_CR25","first-page":"S4","volume":"37","author":"R Grohmann","year":"2004","unstructured":"Grohmann R, Engel RR, Ruther E, Hippius H. The AMSP drug safety program: methods and global results. Pharmacopsychiatry. 2004;37(Suppl 1):S4\u201311.","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"579_CR26","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42(Suppl 1):S90\u20134.","journal-title":"Schizophr Bull"},{"key":"579_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jad.2020.12.073","volume":"281","author":"J Seifert","year":"2021","unstructured":"Seifert J, Engel RR, Bernegger X, Fuhrmann F, Bleich S, Stubner S, et al. Time trends in Pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001\u20132017. J Affect Disord. 2021;281:547\u201356.","journal-title":"J Affect Disord"},{"issue":"1","key":"579_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00406-019-01058-1","volume":"270","author":"T Greiner","year":"2020","unstructured":"Greiner T, Haack B, Toto S, Bleich S, Grohmann R, Faltraco F, et al. Pharmacotherapy of psychiatric inpatients with adjustment disorder: current status and changes between 2000 and 2016. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):107\u201317.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"579_CR29","first-page":"1","volume":"05","author":"S Sarkar","year":"2016","unstructured":"Sarkar S. Psychiatric polypharmacy, etiology and potential consequences. Curr Psychopharmacol. 2016;05:1\u201316.","journal-title":"Curr Psychopharmacol"},{"issue":"12","key":"579_CR30","first-page":"2759","volume":"7","author":"KB Thakkar","year":"2013","unstructured":"Thakkar KB, Jain MM, Billa G, Joshi A, Khobragade AA. A drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital. J Clin Diagn Res. 2013;7(12):2759\u201364.","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"579_CR31","first-page":"1","volume":"8","author":"AA Deshmukh","year":"2020","unstructured":"Deshmukh AA, Dabhade SS, Ghongane BB. A study of psychotropic drugs being prescribed to the patients attending the psychiatric outpatient department in a tertiary care hospital. Iran J Health Sci. 2020;8(3):1\u20139.","journal-title":"Iran J Health Sci"},{"issue":"1","key":"579_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0973-1229.104497","volume":"11","author":"S Kukreja","year":"2013","unstructured":"Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens Sana Monogr. 2013;11(1):82\u201399.","journal-title":"Mens Sana Monogr"},{"key":"579_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/1471-244X-13-231","volume":"13","author":"M Subramaniam","year":"2013","unstructured":"Subramaniam M, He VY, Vaingankar JA, Abdin E, Chong SA. Prevalence of and factors related to the use of antidepressants and benzodiazepines: results from the Singapore mental health study. BMC Psychiatry. 2013;13:231.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"579_CR34","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/aps.2014.50","volume":"35","author":"J Liang","year":"2014","unstructured":"Liang J, Olsen RW. Alcohol use disorders and current Pharmacological therapies: the role of GABA(A) receptors. Acta Pharmacol Sin. 2014;35(8):981\u201393.","journal-title":"Acta Pharmacol Sin"},{"issue":"Suppl 2","key":"579_CR35","first-page":"28","volume":"66","author":"CP O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28\u201333.","journal-title":"J Clin Psychiatry"},{"key":"579_CR36","unstructured":"Deutsche Gf\u00fcr. Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN), Deutsche Gesellschaft f\u00fcr Suchtforschung und Suchttherapie (DG-Sucht). Screening, Diagnose und Behandlung alkoholbezogener St\u00f6rungen2020 18 Sep 2023. Available from: https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/076-001.html00"},{"key":"579_CR37","doi-asserted-by":"publisher","first-page":"173482","DOI":"10.1016\/j.pbb.2022.173482","volume":"221","author":"F Castillo","year":"2022","unstructured":"Castillo F, Jones JD, Luba RR, Mogali S, Foltin RW, Evans SM, et al. Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. Pharmacol Biochem Behav. 2022;221:173482.","journal-title":"Pharmacol Biochem Behav"},{"issue":"7","key":"579_CR38","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/add.13324","volume":"111","author":"RV Smith","year":"2016","unstructured":"Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160\u201374.","journal-title":"Addiction"},{"issue":"1","key":"579_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s43045-020-00029-w","volume":"27","author":"II Mohamed","year":"2020","unstructured":"Mohamed II, Ahmad HEK, Hassaan SH, Hassan SM. Assessment of anxiety and depression among substance use disorder patients: a case-control study. Middle East Curr Psychiatry. 2020;27(1):22.","journal-title":"Middle East Curr Psychiatry"},{"issue":"9","key":"579_CR40","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1093\/ijnp\/pyy048","volume":"21","author":"S St\u00fcbner","year":"2018","unstructured":"St\u00fcbner S, Grohmann R, Greil W, Zhang X, M\u00fcller-Oerlinghausen B, Bleich S, et al. Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP multicenter drug safety surveillance project. Int J Neuropsychopharmacol. 2018;21(9):814\u201321.","journal-title":"Int J Neuropsychopharmacol"},{"key":"579_CR41","doi-asserted-by":"crossref","unstructured":"Guina J, Merrill B, Benzodiazepines I. Upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med. 2018;7(2).","DOI":"10.3390\/jcm7020017"},{"issue":"20","key":"579_CR42","first-page":"355","volume":"116","author":"J Henssler","year":"2019","unstructured":"Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int. 2019;116(20):355\u201361.","journal-title":"Dtsch Arztebl Int"},{"key":"579_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.addbeh.2018.08.027","volume":"97","author":"J Davies","year":"2019","unstructured":"Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav. 2019;97:111\u201321.","journal-title":"Addict Behav"},{"issue":"6","key":"579_CR44","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00406-020-01223-x","volume":"271","author":"MA Reinhard","year":"2021","unstructured":"Reinhard MA, Seifert J, Greiner T, Toto S, Bleich S, Grohmann R. Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries. Eur Arch Psychiatry Clin Neurosci. 2021;271(6):1065\u201376.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"579_CR45","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management2017 12 Feb 2023. Available from: https:\/\/www.gov.uk\/government\/publications\/drug-misuse-and-dependence-uk-guidelines-on-clinical-management"},{"issue":"1","key":"579_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/0023210-200923010-00002","volume":"23","author":"M Lader","year":"2009","unstructured":"Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19\u201334.","journal-title":"CNS Drugs"},{"issue":"12","key":"579_CR47","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.amjmed.2006.02.026","volume":"119","author":"S Bent","year":"2006","unstructured":"Bent S, Padula A, Moore D, Patterson M, Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med. 2006;119(12):1005\u201312.","journal-title":"Am J Med"},{"key":"579_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fpsyt.2020.00035","volume":"11","author":"Y Luo","year":"2020","unstructured":"Luo Y, Kataoka Y, Ostinelli EG, Cipriani A, Furukawa TA. National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: A population representative survey based analysis. Front Psychiatry. 2020;11:35.","journal-title":"Front Psychiatry"},{"key":"579_CR49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fpsyt.2020.00551","volume":"11","author":"Z Yu","year":"2020","unstructured":"Yu Z, Zhang J, Zheng Y, Yu L. Trends in antidepressant use and expenditure in six major cities in China from 2013 to 2018. Front Psychiatry. 2020;11:551.","journal-title":"Front Psychiatry"},{"issue":"3","key":"579_CR50","doi-asserted-by":"publisher","first-page":"e010861","DOI":"10.1136\/bmjopen-2015-010861","volume":"6","author":"D Duncan","year":"2016","unstructured":"Duncan D, Cooke L, Symonds C, Gardner D, Pringsheim T. Quetiapine use in adults in the community: a population-based study in alberta, Canada. BMJ Open. 2016;6(3):e010861.","journal-title":"BMJ Open"},{"issue":"3","key":"579_CR51","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/wps.21010","volume":"21","author":"M H\u00f8jlund","year":"2022","unstructured":"H\u00f8jlund M, Andersen K, Ernst MT, Correll CU, Hallas J. Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study. World Psychiatry. 2022;21(3):444\u201351.","journal-title":"World Psychiatry"},{"issue":"6","key":"579_CR52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.9740\/mhc.2016.11.308","volume":"6","author":"CN Carr","year":"2016","unstructured":"Carr CN, Lopchuk S, Beckman ME, Baugh TB. Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review. Ment Health Clin. 2016;6(6):308\u201313.","journal-title":"Ment Health Clin"},{"issue":"2","key":"579_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00702-023-02589-7","volume":"130","author":"C Glocker","year":"2023","unstructured":"Glocker C, Grohmann R, Burkhardt G, Seifert J, Bleich S, Held T, et al. Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016. J Neural Transm. 2023;130(2):153\u201363.","journal-title":"J Neural Transm"},{"issue":"1","key":"579_CR54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/2279-042X.200987","volume":"6","author":"S Kim","year":"2017","unstructured":"Kim S, Lee G, Kim E, Jung H, Chang J. Quetiapine misuse and abuse: is it an atypical paradigm of drug seeking behavior?? J Res Pharm Pract. 2017;6(1):12\u20135.","journal-title":"J Res Pharm Pract"},{"key":"579_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/DHPS.S296515","volume":"13","author":"JA Jahnsen","year":"2021","unstructured":"Jahnsen JA, Widnes SF, Schj\u00f8tt J, Quetiapine. Misuse and dependency: A Case-Series of questions to a Norwegian network of drug information centers. Drug Healthc Patient Saf. 2021;13:151\u20137.","journal-title":"Drug Healthc Patient Saf"},{"key":"579_CR56","unstructured":"Haack B, Philipp P, Greiner T, Schneider M, Heinze M, Grohmann R et al. Psychotropic prescription patterns of inpatients with mental and behavioral disorders caused by alcohol (F11). 2022. Manuscript submitted for publication."},{"issue":"6","key":"579_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","volume":"28","author":"F Schifano","year":"2014","unstructured":"Schifano F. Misuse and abuse of Pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491\u20136.","journal-title":"CNS Drugs"},{"issue":"1","key":"579_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","volume":"30","author":"O Schjerning","year":"2016","unstructured":"Schjerning O, Rosenzweig M, Potteg\u00e5rd A, Damkier P, Nielsen J. Abuse potential of pregabalin: A systematic review. CNS Drugs. 2016;30(1):9\u201325.","journal-title":"CNS Drugs"},{"issue":"2","key":"579_CR59","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the united States. JAMA Psychiatry. 2015;72(2):136\u201342.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"579_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00406-018-0966-3","volume":"270","author":"A Panes","year":"2020","unstructured":"Panes A, Pariente A, Benard-Laribiere A, Lassalle R, Dureau-Pournin C, Lorrain S, et al. Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):3\u201310.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"579_CR61","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","volume":"17","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327\u201335.","journal-title":"Dialogues Clin Neurosci"},{"issue":"4 Suppl","key":"579_CR62","first-page":"S76","volume":"26","author":"JA Dopheide","year":"2020","unstructured":"Dopheide JA. Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care. 2020;26(4 Suppl):S76\u201384.","journal-title":"Am J Manag Care"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-025-00579-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-025-00579-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:04:25Z","timestamp":1750428265000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-025-00579-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1186\/s13722-025-00579-6","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The evaluated data were obtained from a completely anonymized database, ensuring that subjects could not be traced. Evaluations based on AMSP data were approved by the Ethics Committee of the University of Munich and the Ethics Committee of the Hannover Medical School (Nr. 8100_BO_S_2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Sermin Toto is a member of the advisory board for Otsuka and Janssen-Cilag and has received speaker honoraria from Janssen-Cilag, Lundbeck\/Otsuka, Recordati Pharma GmbH, ROVI GmbH and Servier. Johanna Seifert took part in two educational events sponsored by Otsuka\/Lundbeck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}